Publications by authors named "Mike Bayne"

Claim this Profile
P
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Arne Kolstad, Tim Illidge, Nils Bolstad, Signe Spetalen, Ulf Madsbu, Mike Bayne

Blood Adv· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Simon J Crabb, Karen Martin, Julia Abab, Ian Ratcliffe, Roger Thornton, Mike Bayne

Eur J Cancer· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.
Amelia O Clive, Hazel Taylor, Lee Dobson, Paula Wilson, Emma de Winton, Mike Bayne

Lancet Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.
Tim M Illidge, Sam Mayes, Ruth Pettengell, Andrew T Bates, Mike Bayne

J Clin Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data.
Michael P Mac Manus, Sarah Everitt, Mike Bayne, David Ball, Nikki Plumridge

Radiother Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy.
Tim M Illidge, Mike Bayne, Nicholas S Brown, Samantha Chilton, Mark S Cragg

Blood· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells.
Mark S Cragg, Mike B Bayne, Alison L Tutt, Ruth R French, Stephen Beers

Blood· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apparent modulation of CD20 by rituximab: an alternative explanation.
Mark S Cragg, Mike C Bayne, Timothy M Illidge, Thomas Valerius, Peter W N Johnson

Blood· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy.
Yong Du, Jamie Honeychurch, Mark S Cragg, Mike Bayne, Martin J Glennie

Blood· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis